Jason Harris

The Centers for Medicare & Medicaid Services (CMS) has announced that it will cover certain genomic testing for Medicare-eligible patients with advanced cancer.

The National Comprehensive Cancer Network (NCCN) has added apalutamide (Erleada) to its category 1 recommendations for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

The FDA has granted priority review to a supplemental biologics license application for Pembrolizumab (Keytruda) for the treatment of advanced cervical cancer with disease progression on or after chemotherapy.

Predicting survival outcomes for patients with metastatic triple-negative breast cancer (mTNBC) is now possible using liquid biopsy, according to results from a retrospective study published in the Journal of Clinical Oncology.

A study done at SUNY Downstate Hospital found that black women of Caribbean descent with type I or type II endometrial cancer expressed significant differences in genetic variations when compared with a nationwide population of patients with endometrial cancer.

Pfizer announced that the FDA has granted a priority review to a new drug application for lorlatinib, an ALK inhibitor, for use in patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors.

According to results from an analysis of the Surveillance, Epidemiology, and End Results database of the National Cancer Institute, older adults with colorectal cancer are more likely to develop cardiovascular disease and congestive heart failure.

Trastuzumab (Herceptin) did not reduce cardiac function in women with node-positive, HER2-positive, early-stage breast cancer, according a study published in the Journal of Clinical Oncology.

A new study shows that using the targeted agents lapatinib (Tykerb) and trastuzumab (Herceptin) together, combined with an aromatase inhibitor (AI), significantly reduced the risk of death or progression in women with HER2-positive/HR-positive metastatic breast cancer compared with each single targeted agent in combination with an AI.

Results of a new study show that adding ribociclib (Kisqali) to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival (PFS) when used as a first-line treatment for

A supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) has been granted FDA priority review status for the treatment of adults and children with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL).

Adjuvant therapy is associated with high toxicity and most patients will derive no benefit, Umberto Capitanio, MD, San Raffaele Scientific Institute, Milan, Italy, said in a presentation during the 2017 EMUC Congress. However, adjuvant therapy “might show the highest ratio between clinical benefit and toxicity” in this specific subset of high-risk patients.

The FDA has approved fulvestrant (Faslodex) for use in combination with the CDK4/6 inhibitor abemaciclib (Verzenio) to treat patients with HR+/HER2- advanced or metastatic breast cancer who have progressed after endocrine therapy.

The FDA granted Olaparib (Lynparza) a priority review for the treatment of certain patients with breast cancer.

The FDA has awarded the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) a breakthrough therapy designation for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection.

FDA approval was given to a new regimen of cabazitaxel (Jevtana) to treat men with metastatic castration-resistant prostate cancer who previously received a docetaxel-containing regimen. The approval is for 20 mg/m2 every 3 weeks in combination with prednisone. The agency approved a dose of 25 mg/m2 every 3 weeks in this patient population in 2010.

The FDA announced today that it has approved the first biosimilar for the treatment of multiple types of cancer.

CD19 CAR T-cell therapy induced a high-response rate in patients with high-risk, ibrutinib-refractory chronic lymphocytic leukemia (CLL).

Nivolumab (Opdivo) improved quality of life scores in most patients with head and neck squamous cell carcinoma (HNSCC).

Maintenance rucaparib may improves progression-free survival in patients with ovarian cancer.

The FDA has approved the dabrafenib/trametinib combination for patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC)

The human papillomavirus (HPV) vaccine has reduced the prevalence of high-risk oral HPV infections by 88& in young adults that have had at least 1 dose of the vaccine.

For asymptomatic adults, the US Preventive Services Task Force (USPSTF) recommends against screening for thyroid cancer.

While patients with stage III or IV melanoma who received a higher dose of ipilimumab did live longer than those on a lower dose, there was also greater toxicity.

The UK Myeloma Forum and the British Society for Haematology collaborated to create a comprehensive, multidisciplinary guideline document for the screening, management, and long-term care of patients with myeloma.

New modalities of treatments for patients with Ewing sarcoma have expanded overall survival. However, there are few studies done on the long-term quality of life issues these patients may experience.

There may be a shift away from the USPSTF's opposition to routine PSA screening for prostate cancer in some men.